Dasatinib plus quercetin senolytic therapy: the 2024-2025 human trial update

← Back to articles

Senolytics—agents that selectively eliminate senescent cells—were among the most discussed aging-biology ideas of the late 2010s. The lead human regimen pairs the prescription leukemia drug dasatinib with the dietary flavonoid quercetin (D+Q). Several years and a string of early-phase human studies later, the program has demonstrated feasibility, central-nervous-system penetration, and reductions in senescent-cell markers, but it has not yet produced a positive randomized efficacy result in any disease. Just as importantly, the "senolytic" capsules sold in the supplement aisle are not the regimen that was studied.

The preclinical foundation

D+Q emerged from work at the Mayo Clinic on the anti-apoptotic "survival" networks that let senescent cells resist their own death signals. In aged and disease-model mice, intermittent D+Q dosing improved physical function and several markers of healthspan, and the intermittent "hit-and-run" schedule—dosing for a few days at a time rather than continuously—was important to the effect because dasatinib and quercetin clear the body within hours. One translational study showed the principle extends partway to humans: D+Q raised urinary α-Klotho, a geroprotective protein, in patients with idiopathic pulmonary fibrosis (IPF), mirroring effects seen in mice [1].

The first human studies (2019)

The first human D+Q senolytic study was an open-label, two-center pilot in 14 patients with IPF, a progressive senescence-associated lung disease. Participants took dasatinib 100 mg/day plus quercetin 1,250 mg/day for three days a week over three weeks. The trial met its feasibility endpoints (100% retention, one serious adverse event), and physical function—6-minute walk distance, 4-meter gait speed, and chair-stand time—improved significantly, though there was no placebo group and pulmonary function did not change [2]. Months later, an open-label study in 9 patients with diabetic kidney disease provided the first direct human evidence that D+Q actually reduces senescent-cell burden: adipose-tissue cells expressing senescence markers (p16, p21, senescence-associated β-galactosidase) and several circulating inflammatory SASP factors fell within 11 days of a three-day course [3].

What the 2024–2025 human data add

The newer human work has refined the toolkit more than it has proven benefit. A phase 1 open-label study in 5 older adults with early Alzheimer's disease (NCT04063124) confirmed that dasatinib penetrates the central nervous system and was well tolerated; exploratory 2025 biomarker analyses found some treatment-associated changes in cerebrospinal-fluid and plasma markers but, by design, could not establish cognitive efficacy in so small a sample [4]. In a separate placebo-controlled trial in postmenopausal women (NCT04313634), researchers reported in 2025 that women with the highest baseline senescent-cell burden (measured by a T-cell p16 assay) had the most robust skeletal responses to D+Q—an intriguing biomarker-selection finding rather than a population-wide efficacy claim [5]. Additional D+Q pilots, including one in older adults with treatment-resistant depression and schizophrenia (NCT05838560), have published protocols and are underway, but none has reported definitive clinical efficacy [6].

It is worth being precise about what these studies have and have not established, because the distinction is where most of the public confusion lives. "Target engagement" means the drug reaches and acts on its intended target—here, that D+Q lowers measurable senescent-cell markers and that dasatinib gets into tissues including the brain. The human studies have shown that. "Clinical efficacy" means patients actually live longer, function better, or get sick less—and that has not been demonstrated in any adequately powered, placebo-controlled D+Q trial to date. The pilots were designed to test feasibility, safety, and biomarkers in small numbers, not to prove benefit, so the absence of a definitive efficacy result is expected rather than a failure. The honest status is that the foundational hypothesis remains open: clearing senescent cells appears to change the right biology in people, but whether that translates into better health outcomes is still being tested.

Why supplement-aisle "senolytic" products are different

Consumer "senolytic" supplements typically contain fisetin, quercetin, theaflavins, or proprietary polyphenol blends. None of these has been shown to act as a single-agent senolytic in a placebo-controlled human trial. In the studied regimen, quercetin was a partner to dasatinib—and dasatinib, a prescription tyrosine-kinase inhibitor, is the component doing most of the senolytic work in the laboratory. It is by definition absent from any supplement. Fisetin is in active human testing as a candidate senolytic but has not yet delivered confirmatory efficacy data, and supplement doses are generally lower than the doses used in research [3].

Safety considerations

Dasatinib is FDA-approved for chronic myelogenous leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia, with recognized risks including pleural effusion, pulmonary arterial hypertension, thrombocytopenia and bleeding, and QT prolongation. The intermittent senolytic schedule uses lower cumulative exposure than oncology dosing, but it is not risk-free, and in the IPF pilot the most common adverse effects were respiratory symptoms, bruising, and gastrointestinal discomfort [2]. Quercetin at gram-level doses is generally well tolerated but inhibits CYP3A4 and can raise levels of co-administered drugs. The combination should not be self-administered outside a trial; the prescription drug, the dosing schedule, and the monitoring all matter.

Sources

1. Zhu Y, Prata LGPL, Gerdes EOW, et al. "Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans." EBioMedicine, 2022;77:103912. PMID 35292270.
2. Justice JN, Nambiar AM, Tchkonia T, et al. "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." EBioMedicine, 2019;40:554–563. PMID 30616998.
3. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease." EBioMedicine, 2019;47:446–456. PMID 31542391.
4. Garbarino VR, Palavicini JP, Melendez J, et al. "Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease." Neurotherapeutics, 2025;22(4):e00591. PMID 40274471.
5. Farr JN, Monroe DG, Atkinson EJ, et al. "Characterization of Human Senescent Cell Biomarkers for Clinical Trials." Aging Cell, 2025;24(5):e14489. PMID 39823170.
6. Schweiger A, Diniz B, Nicol G, et al. "Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders." F1000Research, 2024;13:1072. PMID 40443429.